IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.66B
5Y Perf.+83.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IMVT vs DAWN
Revenue, margins, valuation, and 5-year total return — side by side.
DAWN
Day One Biopharmaceuticals, Inc.
Biotechnology
Market Cap$2.22B
5Y Perf.-9.5%
IMVT vs DAWN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IMVT | DAWN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $5.66B | $2.22B |
| Revenue (TTM) | $0.00 | $158M |
| Net Income (TTM) | $-464M | $-107M |
| Gross Margin | — | 89.1% |
| Operating Margin | — | -80.8% |
| Total Debt | $98K | $3M |
| Cash & Equiv. | $714M | $197M |
IMVT vs DAWN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IMVT
DAWN
| Stock | May 21 | May 26 | Return |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 100 | 183.6 | +83.6% |
| Day One Biopharmace… (DAWN) | 100 | 90.5 | -9.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IMVT vs DAWN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DAWN leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Immunovant, Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 179.8% 10Y total return vs DAWN's -8.4%
- Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
- 3.2% margin vs DAWN's -67.8%
Best for: long-term compounding and sleep-well-at-night
DAWN
Day One Biopharmaceuticals, Inc.
The Income Pick
DAWN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.35
- Rev growth 20.6%, EPS growth -2.0%
- Beta 0.35, current ratio 8.02x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | DAWN | 20.6% revenue growth vs IMVT's -21.3% |
| Quality / Margins | IMVT | 3.2% margin vs DAWN's -67.8% |
| Stability / Safety | DAWN | Beta 0.35 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DAWN | +187.8% vs IMVT's +82.9% |
| Efficiency (ROA) | DAWN | -20.7% ROA vs IMVT's -44.1% |
IMVT vs DAWN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
IMVT vs DAWN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDAWNLAGGINGIMVT
IMVTImmunovant, Inc.
0leads
DAWNDay One Biopharmaceut…
5leads
6 Total Categories
CATEGORYLEADERvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DAWN1/1
Valuation MetricsMultiples, price ratios, and targets
DAWN2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DAWN4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DAWN4/6
Risk & VolatilityBeta, volatility, and downside exposure
DAWN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DAWN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
DAWN and IMVT operate at a comparable scale, with $158M and $0 in trailing revenue.
| Metric | IMVTImmunovant, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $158M |
| EBITDAEarnings before interest/tax | -$487M | -$124M |
| Net IncomeAfter-tax profit | -$464M | -$107M |
| Free Cash FlowCash after capex | -$423M | -$108M |
| Gross MarginGross profit ÷ Revenue | — | +89.1% |
| Operating MarginEBIT ÷ Revenue | — | -80.8% |
| Net MarginNet income ÷ Revenue | — | -67.8% |
| FCF MarginFCF ÷ Revenue | — | -68.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +83.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | +70.0% |
DAWN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
DAWN leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | IMVTImmunovant, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| Market CapShares × price | $5.7B | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $4.9B | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | -10.20x | -20.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 14.06x |
| Price / BookPrice ÷ Book value/share | 5.96x | 5.05x |
| Price / FCFMarket cap ÷ FCF | — | — |
DAWN leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
DAWN leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
DAWN delivers a -23.4% return on equity — every $100 of shareholder capital generates $-23 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to DAWN's 0.01x. On the Piotroski fundamental quality scale (0–9), DAWN scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | IMVTImmunovant, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| ROE (TTM)Return on equity | -47.1% | -23.4% |
| ROA (TTM)Return on assets | -44.1% | -20.7% |
| ROICReturn on invested capital | — | -30.5% |
| ROCEReturn on capital employed | -66.1% | -26.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.01x |
| Net DebtTotal debt minus cash | -$714M | -$194M |
| Cash & Equiv.Liquid assets | $714M | $197M |
| Total DebtShort + long-term debt | $98,000 | $3M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
DAWN leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DAWN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,976 today (with dividends reinvested), compared to $9,162 for DAWN. Over the past 12 months, DAWN leads with a +187.8% total return vs IMVT's +82.9%. The 3-year compound annual growth rate (CAGR) favors DAWN at 16.3% vs IMVT's 13.2% — a key indicator of consistent wealth creation.
| Metric | IMVTImmunovant, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| YTD ReturnYear-to-date | +7.4% | +143.3% |
| 1-Year ReturnPast 12 months | +82.9% | +187.8% |
| 3-Year ReturnCumulative with dividends | +45.0% | +57.4% |
| 5-Year ReturnCumulative with dividends | +69.8% | -8.4% |
| 10-Year ReturnCumulative with dividends | +179.8% | -8.4% |
| CAGR (3Y)Annualised 3-year return | +13.2% | +16.3% |
DAWN leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
DAWN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DAWN is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DAWN currently trades 100.0% from its 52-week high vs IMVT's 92.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMVTImmunovant, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.37x | 0.35x |
| 52-Week HighHighest price in past year | $30.09 | $21.53 |
| 52-Week LowLowest price in past year | $13.36 | $5.64 |
| % of 52W HighCurrent price vs 52-week peak | +92.5% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 55.8 | 80.3 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 4.8M |
DAWN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates IMVT as "Buy" and DAWN as "Buy". Consensus price targets imply 63.4% upside for IMVT (target: $46) vs 10.3% for DAWN (target: $24).
| Metric | IMVTImmunovant, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $45.50 | $23.75 |
| # AnalystsCovering analysts | 23 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DAWN leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallDay One Biopharmaceuticals,… (DAWN)Leads 5 of 6 categories
Loading custom metrics...
IMVT vs DAWN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IMVT or DAWN a better buy right now?
Analysts rate Immunovant, Inc.
(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMVT or DAWN?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +69. 8%, compared to -8. 4% for Day One Biopharmaceuticals, Inc. (DAWN). Over 10 years, the gap is even starker: IMVT returned +179. 8% versus DAWN's -8. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMVT or DAWN?
By beta (market sensitivity over 5 years), Day One Biopharmaceuticals, Inc.
(DAWN) is the lower-risk stock at 0. 35β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 288% more volatile than DAWN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 1% for Day One Biopharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — IMVT or DAWN?
On earnings-per-share growth, the picture is similar: Day One Biopharmaceuticals, Inc.
grew EPS -2. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IMVT or DAWN?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -67. 8% for Day One Biopharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -80. 8% for DAWN. At the gross margin level — before operating expenses — DAWN leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — IMVT or DAWN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IMVT or DAWN better for a retirement portfolio?
For long-horizon retirement investors, Day One Biopharmaceuticals, Inc.
(DAWN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35)). Both have compounded well over 10 years (DAWN: -8. 4%, IMVT: +179. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IMVT and DAWN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IMVT is a small-cap quality compounder stock; DAWN is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.